Equities analysts predict that OPKO Health, Inc. (NASDAQ:OPK) will announce sales of $457.57 million for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for OPKO Health’s earnings, with the lowest sales estimate coming in at $454.90 million and the highest estimate coming in at $460.00 million. OPKO Health posted sales of $301.20 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 51.9%. The company is expected to announce its next quarterly earnings results on Thursday, July 29th.
According to Zacks, analysts expect that OPKO Health will report full year sales of $1.81 billion for the current financial year, with estimates ranging from $1.70 billion to $1.95 billion. For the next financial year, analysts expect that the company will post sales of $1.49 billion, with estimates ranging from $1.40 billion to $1.62 billion. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover OPKO Health.
OPKO Health (NASDAQ:OPK) last issued its quarterly earnings data on Wednesday, April 28th. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.05. OPKO Health had a negative return on equity of 2.61% and a negative net margin of 9.79%.
In other news, CEO Phillip Md Et Al Frost bought 75,000 shares of the business’s stock in a transaction on Monday, May 10th. The stock was purchased at an average cost of $3.65 per share, for a total transaction of $273,750.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $11,201,671.15. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders acquired 925,000 shares of company stock valued at $4,028,000 over the last 90 days. 40.90% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Baillie Gifford & Co. bought a new position in shares of OPKO Health in the first quarter valued at $31,000. Clear Harbor Asset Management LLC increased its holdings in shares of OPKO Health by 10,000.0% in the fourth quarter. Clear Harbor Asset Management LLC now owns 10,100 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 10,000 shares in the last quarter. Matrix Asset Advisors Inc. NY bought a new position in shares of OPKO Health in the fourth quarter valued at $40,000. Beacon Pointe Advisors LLC bought a new position in shares of OPKO Health in the fourth quarter valued at $40,000. Finally, Linscomb & Williams Inc. bought a new position in shares of OPKO Health in the fourth quarter valued at $43,000. 28.51% of the stock is currently owned by institutional investors.
OPK traded up $0.04 during trading on Friday, reaching $3.46. The stock had a trading volume of 160,340 shares, compared to its average volume of 6,818,914. The firm has a market capitalization of $2.32 billion, a price-to-earnings ratio of -19.00, a price-to-earnings-growth ratio of 5.84 and a beta of 1.98. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.13. OPKO Health has a 1-year low of $2.08 and a 1-year high of $6.47. The stock has a 50 day moving average of $4.24 and a two-hundred day moving average of $4.42.
About OPKO Health
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units, as well as 4Kscore prostate cancer testing services.
Read More: What is total return in investing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.